AOD-9604

Research Use

Also known as hGH fragment 176-191

Interaction Warning1 flagged

Do not combine AOD-9604 with the following:

Redundant stacking with full GH or GHRPs

Function

Primary

Fat metabolism · Weight management

Secondary

Cartilage repair (off-label)

Mechanism

C-terminal fragment of hGH — activates fat-specific β3-adrenergic receptor; promotes lipolysis without GH's anabolic/diabetogenic effects; possible cartilage regeneration via VEGF.

Evidence

Pre-clinical / Observational

Research

Phase II/III completed (failed primary obesity endpoint)

Dosing

Range

300–600 mcg/day

Frequency

Once daily (fasted)

Route

Subcutaneous

Administration & Technique

Subcutaneous (SubQ)

Default route for most research and therapeutic peptides — best absorption for reconstituted powder.

Device31G × 5/16" insulin syringe (U-100). 100 units = 1 mL.

TechniquePinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.

Cycling

8 weeks on / 4 weeks off.

Timing & Interactions

When to take

Once daily fasted (morning) SubQ. Wait 30 min before eating.

Do not combine with

·Redundant stacking with full GH or GHRPs

Complements

·Standalone or paired with caloric deficit + training

Storage & Reconstitution

Powder (Pre-Reconstitution)

Lyophilized powder: refrigerate 2–8°C for up to 24 months, or freeze at –20°C for extended storage. Keep sealed, desiccated, and protected from light.

After Reconstitution

After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Discard if cloudy, discolored, or precipitated.

Notes

Do not freeze after reconstitution — freeze/thaw cycles degrade most peptides.

Full BAC water & reconstitution guide →

Benefits

·Selective lipolysis without GH side effects
·No insulin resistance signal
·No IGF-1 elevation

Risks

·Failed Phase III obesity endpoint
·Limited long-term human data

Contraindications

·Pregnancy
·Hypersensitivity

Regulatory

Not FDA-approved; TGA-approved (Australia, discontinued); research use

Veterinary Use (Pets)

Fragment of GH used in canine and equine weight-loss and joint-support protocols.

Dogs (Canine)

Dose2–5 mcg/kg once daily fasted

RouteSubQ

UseObesity, osteoarthritis adjunct.

Horses (Equine)

Dose500 mcg per horse daily

RouteSubQ

UseMetabolic syndrome, joint support.

Full veterinary reference →

Functional Groups

Weight Loss Recovery

Cited Works

Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604). J Clin Endocrinol Metab. 2001;86:5663.source

View full reference repository →